Skip to main content

Table 1 Baseline characteristics of subjects receiving Placebo, Phyllanthus emblica 250 mg and Phyllanthus emblica 500 mg

From: Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: a randomised, double blind, placebo controlled clinical study

Parameter Placebo (A) (n = 18) Phyllanthus emblica 250 mg (B) (n = 20) Phyllanthus emblica 500 mg (C) (n = 21)
Age in Yrs. 56.89 ± 7.39 57.45 ± 7.44 57.24 ± 8.94
Gender (M/F) 14/4 14/6 15/6
Bodyweight (Kg) 78.17 ± 5.94 78.9 ± 6.61 78.9 ± 4.87
Height (cm) 161.17 ± 2.77 162.20 ± 3.53 162.14 ± 2.83
BMI (Kg/m2) 30.11 ± 1.72 30.02 ± 1.66 30.05 ± 1.70
BMI (kg/m2) < 30 5 (28%) 7 (35%) 6 (29%)
>  30 13 (72%) 13 (65%) 15 (71%)
SBP (mmHg) < 130 5 (28%) 7 (35%) 9 (43%)
> 130 13 (72%) 13 (65%) 12(57%)
DBP (mmHg) <  85 10(56%) 12(60%) 8(38%)
>  85 8 (44%) 8 (40%) 13 (62%)
FPG (mg /dL) < 100 13 (72%) 11 (55%) 8(38%)
> 100 5 (28%) 9 (45%) 13 (62%)
  1. Values expressed as mean ± SD
  2. SD standard deviation, BMI Body Mass Index, SBP Systolic blood pressure, DBP Diastolic blood pressure, FPG Fasting plasma glucose
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us